Podcast

Breaking Barriers: An Egyptian Immigrant's Journey with ALL

Author(s):

Kristie L. Kahl

In this episode of the “CURE Talks Cancer” podcast, we spoke with Bishoy Tadros, who went on to break barriers after he was diagnosed with acute lymphoblastic leukemia at the age of 3 and immigrated to the United States from Egypt to receive treatment.

At the age of 3, Bishoy Tadros received a diagnosis of acute lymphoblastic leukemia and immigrated to the United States with him family to receive treatment.

After moving to Los Angeles and then to Long Island, New York, Tadros underwent varios aggressive surgeries and entered remission on his 13th birthday.

However, it wasn’t until 2017 that he was inspired to share his story. He pushed away from his comfort zone, entering to run the New York City Marathon and raising money for the Leukemia and Lymphoma Society — all of which helped him to realize the power of his personal story.

Tadros wrote a memoir, titled “Break Barriers,” to help individuals learn that setbacks are never instilled to define oneself, and that patience, perspective and purpose are key.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
Image of FDA sign.
April 8th 2025

FDA Grants Positive Review for AML Drug Trial, First Dosing in 2025

Spencer Feldman
The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory leukemia or lymphoma: © nobeatsoffierce - stock.adobe.com
March 22nd 2025

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

Alex Biese
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Nutrition is a challenge for many patients with cancer. © - stock.adobe.com
March 12th 2025

Nutrition is Key Following a Cancer Diagnosis

The Leukemia & Lymphoma Society
Nutrition is a challenge for many patients with cancer.
Cancer is one of the most expensive medical conditions to treat in the U.S. - © stock.adobe.com
March 12th 2025

The Leukemia & Lymphoma Society is Helping Patients With Medial Debt

The Leukemia & Lymphoma Society
Cancer is one of the most expensive medical conditions to treat in the U.S.